JP2025510414A5 - - Google Patents

Info

Publication number
JP2025510414A5
JP2025510414A5 JP2025502799A JP2025502799A JP2025510414A5 JP 2025510414 A5 JP2025510414 A5 JP 2025510414A5 JP 2025502799 A JP2025502799 A JP 2025502799A JP 2025502799 A JP2025502799 A JP 2025502799A JP 2025510414 A5 JP2025510414 A5 JP 2025510414A5
Authority
JP
Japan
Prior art keywords
disease
compound
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025502799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510414A (ja
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed filed Critical
Priority claimed from PCT/US2023/064967 external-priority patent/WO2023183943A1/en
Publication of JP2025510414A publication Critical patent/JP2025510414A/ja
Publication of JP2025510414A5 publication Critical patent/JP2025510414A5/ja
Pending legal-status Critical Current

Links

JP2025502799A 2022-03-25 2023-03-24 NLRP3誘導体として有用なピリド-[3,4-d]ピリダジンアミン誘導体 Pending JP2025510414A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US17/704,983 2022-03-25
US202263420930P 2022-10-31 2022-10-31
US63/420,930 2022-10-31
US202363443874P 2023-02-07 2023-02-07
US63/443,874 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (2)

Publication Number Publication Date
JP2025510414A JP2025510414A (ja) 2025-04-14
JP2025510414A5 true JP2025510414A5 (cg-RX-API-DMAC7.html) 2026-04-02

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025502799A Pending JP2025510414A (ja) 2022-03-25 2023-03-24 NLRP3誘導体として有用なピリド-[3,4-d]ピリダジンアミン誘導体

Country Status (13)

Country Link
EP (1) EP4499638A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510414A (cg-RX-API-DMAC7.html)
KR (1) KR20250005125A (cg-RX-API-DMAC7.html)
CN (1) CN119137121A (cg-RX-API-DMAC7.html)
AU (1) AU2023238121A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246681A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002855A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013702A2 (cg-RX-API-DMAC7.html)
IL (1) IL315842A (cg-RX-API-DMAC7.html)
MX (1) MX2024011697A (cg-RX-API-DMAC7.html)
PE (1) PE20250605A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345836A (cg-RX-API-DMAC7.html)
WO (1) WO2023183943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors

Similar Documents

Publication Publication Date Title
See et al. Choosing a skeletal muscle relaxant
EA016687B8 (ru) Производные циклопропиламида
JP2013139446A5 (cg-RX-API-DMAC7.html)
JP2022540935A5 (cg-RX-API-DMAC7.html)
JP2022153638A5 (cg-RX-API-DMAC7.html)
JP2022515293A5 (cg-RX-API-DMAC7.html)
JP2016199576A5 (cg-RX-API-DMAC7.html)
JP2013535437A5 (cg-RX-API-DMAC7.html)
Tsaousi et al. Implementation of magnesium sulphate as an adjunct to multimodal analgesic approach for perioperative pain control in lumbar laminectomy surgery: a randomized placebo-controlled clinical trial
HRP20180487T1 (hr) Upotreba flekainida kao anti-koneksinskog sredstva i metoda za potenciranje učinaka psihotropnog lijeka
JP2008501717A (ja) 疼痛処置のためのカプサイシノイド、局所麻酔薬および/または鎮痒薬を含有する処方物
KR20080103043A (ko) 우울증 환자에게 있는 수면 장애의 치료를 위해 의도된 치료제를 수득하기 위한 아고멜라틴의 사용
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2015500223A5 (cg-RX-API-DMAC7.html)
JP2024543135A5 (cg-RX-API-DMAC7.html)
JP2022539152A5 (cg-RX-API-DMAC7.html)
JP2022500445A5 (cg-RX-API-DMAC7.html)
JP2014523888A5 (cg-RX-API-DMAC7.html)
JP2022550919A5 (cg-RX-API-DMAC7.html)
Rodriguez et al. ERAS protocols and multimodal pain management in surgery
JP2023518640A5 (cg-RX-API-DMAC7.html)
JP2013537901A5 (cg-RX-API-DMAC7.html)
JP2025506201A5 (cg-RX-API-DMAC7.html)
CN119212690A (zh) 包含meai和n-酰基乙醇胺的组合物及其用途
JP2016525543A5 (cg-RX-API-DMAC7.html)